Search results for "Crohn"
showing 10 items of 379 documents
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study.
2017
Background: More than 50% of patients with Crohn's disease require intestinal resection at least once. Postoperative recurrence (POR) is almost uniform if prophylactic treatment is not started early. Endoscopic monitoring is generally advised. We studied the incidence and management of recurrence in patients who had undergone intestinal resection. Methods: Practicrohn was an observational retrospective study performed in 26 Spanish hospitals including patients aged >= 18 years who underwent Crohn's disease-related ileocolonic resection between January 2007 and December 2010. We recorded preventive treatments, the incidence of clinical recurrence in daily practice, and associated risk factor…
Relación de los linfocitos B1 (CD 19+ CD 15+) con la Enfermedad de Crohn
2015
La EC es un proceso inflamatorio crónico y recidivante, sin tendencia a la curación, que puede afectar a todo el tracto gastrointestinal. Se piensa que resulta de una respuesta inmune aberrante y continua contra la microbiota intestinal, catalizada por una susceptibilidad genética individual y múltiples factores medioambientales. Aunque hay múltiples conocimientos sobre su fisiopatología, su etiología permanece desconocida. Hay varias teorías que se han descrito en las últimas décadas para hipotetizar sobre la etiología de la EC: la teoría infecciosa, la autoinmune, la genética, la de la higiene y la autoinflamatoria. En los últimos años, se está definiendo la EC como una inmunodeficiencia,…
Estudio del appel de los linfocitos gamma-delta en la enfermedad de Crohn
2015
La EII es un proceso inflamatorio crónico y recidivante de carácter sistémico que afecta predominantemente al tracto gastrointestinal, asociándose frecuentemente con manifestaciones extraintestinales . Existen dos subtipos principales de EII: la enfermedad de Crohn (EC) y la colitis ulcerosa (CU). La EC puede afectar cualquier parte del tracto digestivo, es de carácter transmural y suele afectar a individuos jóvenes, alternando periodos de remisión clínica y brotes de actividad. El control clínico de estos brotes recidivantes requiere el empleo de fármacos antiinflamatorios no exentos de efectos secundarios (corticoides, inmunosupresores, agentes biológicos etc.) siendo frecuente la necesid…
Una anoressia “infiammatoria”
2020
Crohn's disease (CD) is an inflammatory disease with a chronic relapsing course and a wide spectrum of manifestations that sometimes overlaps the symptoms of other pathologies. The paper describes the case of a girl with anorexia and a following diagnosis of CD.
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…
2021
The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2
Postoperative maintenance therapy for inflammatory bowel disease.
2006
. Curr Opin Gastroenterol. 2006 Jul;22(4):377-81. Postoperative maintenance therapy for inflammatory bowel disease. Cottone M, Orlando A, Modesto I. Department of General Medicine, Pneumology and Nutrition Clinic, Palermo University, Palermo, Italy. PURPOSE OF REVIEW: This review will highlight the knowledge gained from studies published in the year 2005 on maintenance treatment after surgery for inflammatory bowel diseases. RECENT FINDINGS: In Crohn's disease the role of smoking in increasing the risk of relapse and recurrence after surgery is confirmed. Ornidazole seems effective in reducing endoscopic recurrence and clinical relapse after surgery. Probiotics do not appear to be effective…
Mesalazine for the treatment of inflammatory bowel disease
2013
Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combinin…
An update on medical management on Crohn's disease.
2014
The management of Crohn's disease (CD) is continuously evolving. New issues emerging from more recent studies could influence the decision-making process in clinical practice.The aim of this review article is to highlight critical issues on the management of CD, new evidence from clinical trials, long-term prospective studies and real life experience, beyond the current guidelines.The role of mucosal healing in clinical practice is uncertain, clinical remission remains the primary end point. The timing for the definition of steroid-resistant CD should be considered between 2 and 4 weeks. Early treatment strategy with immunomodulators is effective for inducing remission but no controlled dat…
The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?
2016
Sir, We read with interest the recent work by Peyrin-Biroulet and colleagues on the long-term outcome for patients starting anti-TNF monotherapy for Crohn’s disease [CD] and for those needing the addition of an immunomodulator [IM].1 We agree with the main finding of the study, i.e. starting with anti-TNF monotherapy does not worsen long-term disease outcomes. This is in line with data from the literature2 and with our recent prospective study on the concomitant use of an IM and infliximab [IFX] in patients with CD or ulcerative colitis who have had a primary or secondary non-response to IFX monotherapy3: …
Veränderungen im klinischen Bild und der chirurgischen Therapie bei Morbus Crohn Erfahrungen aus 10 Jahren
1998
Changes in clinical presentation of Crohn's disease (CD), patients' age at the time of disease manifestation and operation, general condition and duration of medical management were investigated in a retrospective study. 395 operations for CD were divided into consecutive groups and analysed. In an increasing number of cases patients presented with the "fibrostenotic type" rather than the "fistulizing type" of complaints. The duration of disease and of medical management increased. Patients in later groups were younger and in better general condition. We found a rise in frequency of patients with recurrent CD or prior abdominal surgery for other reasons. Primary surgery for CD increasingly …